Cerus Corporation logo
Cerus Corporation CERS
$ 2.57 0.19%
report update icon

Quarterly report 2026-Q2
added 07-30-2026

Cerus Corporation Income Statement 2025-2008 | CERS

Brief overview of revenue and earnings at Cerus Corporation

The overview follows changes across a five-year period. According to figures from Cerus Corporation, revenue changed from 114 million dollars to 234 million dollars over five years. The cumulative result was +104.6%, corresponding to roughly 15.4% per year. Revenue followed a strong upward trend without signs of stagnation.

The operating result measured by EBITDA moved from −$55.2 million to −$7.3 million, or +86.9%. EBITDA underperformed the top-line trend. EBITDA margin was −48.3% at the start and −3.1% at the end. Higher profitability strengthens the quality of operating growth.

The net financial result changed from −$59.9 million to −$15.6 million. The loss reduction is constructive, but the recovery is incomplete.

The five-year change in capitalization reached −56.3%: from 1.1 billion dollars to 496 million dollars. Investors remain cautious despite better financial results.

Overall conclusion

The financial profile remains mixed, with strengths and risks moving in different directions. Key strengths include higher operating efficiency, net-income growth and sales growth. The overall view is constrained by a weaker market valuation and a narrow EBITDA buffer. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement Cerus Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

496 M 301 M 357 M 459 M 1.17 B 1.13 B 583 M 753 M 515 M 420 M 522 M 399 M 424 M 171 M 133 M 129 M 40.7 M -

Shares

191 M 185 M 180 M 177 M 171 M 164 M 140 M 132 M 108 M 102 M 96.1 M 74.8 M 67.6 M 54.5 M 48 M 40.3 M 34.8 M -

Historical Prices

2.6 1.63 1.98 2.6 6.81 6.92 4.22 5.07 3.38 4.35 6.32 6.24 6.45 3.16 2.8 3.2 1.17 5.05

Net Income

-15.6 M -20.9 M -37.5 M -42.8 M -54.4 M -59.9 M -71.2 M -57.6 M -60.6 M -62.9 M -55.9 M -38.8 M -43.3 M -15.9 M -17 M -16.9 M -24.1 M -

Revenue

234 M 201 M 187 M 188 M 160 M 114 M 93.8 M 76.1 M 51.3 M 39.3 M 34.2 M 36.4 M 39.7 M 36.7 M 33 M 23.1 M 18 M -

Cost of Revenue

- - - - - - 33.4 M 31.6 M 22.5 M 20.3 M - - - - - - - -

Gross Profit

- - - - - - 60.4 M 44.4 M 28.8 M 19 M 10.8 M 15.2 M 17.1 M 16.1 M 14.5 M 9.63 M 5.4 M -

Operating Income

-8.68 M -14.2 M -30.1 M -34.1 M -48.9 M -58.3 M -66.2 M -55 M -57.5 M -61.4 M -61.1 M -44.5 M -28.3 M -17.3 M -15.9 M -16 M -23.8 M -

Interest Expense

3.02 M 1.98 M 8.39 M 5.83 M 4.92 M 3.75 M 6.06 M 4.01 M 3.02 M 2.44 M 1.7 M 599 K 332 K 551 K 964 K 689 K 10 K -

EBITDA

-7.26 M -12.4 M -27.5 M -31.1 M -45.8 M -55.2 M -63.8 M -53.5 M -57.3 M -61.1 M -60.9 M -44.3 M -28.1 M -17.1 M -15.7 M -15.1 M -23 M -

Operating Expenses

149 M 135 M 147 M 147 M 145 M 131 M 127 M 99.4 M 86.3 M 80.3 M 71.8 M 59.7 M 45.4 M 33.4 M 30.4 M 27 M 29.2 M -

General and Administrative Expenses

80.9 M 75.9 M 75.5 M 83.3 M 81.3 M 67 M 66.2 M 56.8 M 52.4 M 48.8 M 46 M 37.7 M 30 M 25.7 M 23.1 M 21.6 M 21.9 M -

All numbers in USD currency

Quarterly Income Statement Cerus Corporation

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

201 M 194 M 192 M 191 M 187 M 185 M 185 M 182 M 181 M 181 M 178 M - 177 M 177 M 174 M 174 M 172 M 171 M 169 M 168 M 167 M 164 M 157 M 144 M 141 M 138 M 137 M 137 M 134 M 131 M 125 M 116 M 110 M 105 M 104 M 103 M 103 M 102 M 99.5 M 99.1 M 96.9 M 95.7 M 93.4 M 80.4 M 75.2 M 72.9 M 72.1 M 71.9 M 69.8 M 69.7 M 59.7 M 56.3 M 54.9 M 54.4 M 53.1 M 51.2 M 47.7 M 47.6 M 47.4 M

Net Income

-2.94 M -1.64 M -19 K -5.71 M -7.72 M -2.93 M -5.78 M -9.69 M -7.27 M -13.3 M -15.6 M - -8.48 M -8.39 M -12.3 M - -12.4 M -15.4 M -17.5 M - -14.1 M -14.9 M -16.5 M -16.9 M -18 M -17.6 M -18.8 M -16.2 M -14.2 M -13.3 M -13.9 M -11.5 M -13.4 M -17.1 M -18.6 M -13.5 M -14.4 M -18.2 M -16.9 M -14.8 M -15.7 M -16 M -9.46 M -20.2 M -10.8 M -7.59 M -225 K -5.86 M -20.5 M -6.72 M -10.3 M -1.72 M -3.46 M -1.91 M -8.83 M -7.74 M 2.26 M -6.41 M -5.1 M

Revenue

57.4 M 53.7 M - - 43.2 M - - - - - - - - - - - - - - - - - - - - - - - 15.4 M 15.4 M - - 10.8 M 9.52 M - - - - - - - - - - - - - - - - - - 8.25 M 9.22 M 8.78 M - 9.25 M 6.75 M 6.62 M

Cost of Revenue

- - - - - - - - - - - - - - - - 17.6 M 15.3 M 11.1 M - 11 M 9.7 M 8.32 M - 7.58 M 8.11 M 8.43 M - 8.14 M 7.72 M 7.33 M - 5.35 M 4.36 M - - - - - - 5.56 M - - - 5.69 M - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 5.45 M 5.16 M 3.31 M 4.52 M 4.72 M 4.28 M 3.37 M 3.49 M 2.48 M 1.8 M 2.98 M 3 M 4.67 M 3.85 M 3.71 M 4.29 M 3.72 M 4.4 M 4.64 M 5.41 M 3.84 M 3.65 M 3.18 M 3.69 M 4.52 M 2.68 M 3.09 M

Operating Income

-1.86 M -354 K 1.24 M -3.42 M -5.85 M -961 K -3.84 M -7.98 M -5.24 M -11.6 M -14.1 M - -7.45 M -6.84 M -9.85 M - -11.1 M -14.4 M -16.4 M - -14 M -14.6 M -15.4 M - -17 M -16.8 M -16.1 M - -13.6 M -12.6 M -13.4 M - -12.4 M -16.2 M -18.1 M - -14.3 M -16.7 M -15.3 M - -16.2 M -15.5 M -14.4 M - -11.4 M -11 M -9.22 M -7.81 M -8.42 M -7.11 M -4.96 M -3.6 M -4.33 M -4.8 M -4.57 M -3.33 M -2.72 M -5.57 M -4.3 M

Interest Expense

734 K 519 K 976 K 845 K 606 K 604 K 412 K 452 K 233 K 2.18 M 1.61 M - 1.41 M 1.35 M 1.38 M - 1.28 M 1.34 M 972 K - 930 K 929 K 935 K - 1.03 M 1.15 M 2.92 M - 1.05 M 958 K 915 K - 1.09 M 501 K 531 K - 586 K 658 K 655 K - 505 K 301 K 255 K - 249 K 34 K 50 K - 41 K 107 K 131 K - 136 K 135 K 139 K - 394 K 220 K 233 K

EBITDA

-950 K 93 K - - -5.55 M - - -7.35 M - - -13.5 M - -5.11 M -6.84 M -8.98 M - -8.79 M -14.4 M -15.7 M - -11.7 M -13.1 M -14.7 M - -15.2 M -15.7 M -15.7 M - -12.5 M -11.8 M -12.9 M - -11 M -15.3 M -17.6 M - -12.9 M -15.8 M -14.9 M - -15 M -14.7 M -13.9 M - -10.4 M -10.4 M -8.89 M -7.76 M -8.02 M -6.82 M -4.79 M -3.55 M -3.75 M -4.4 M -4.36 M -3.28 M -2.02 M -5.05 M -4.03 M

Operating Expenses

37.3 M 34.5 M 34.4 M 40.1 M 36.9 M 31.8 M 33.9 M 34.3 M 34.5 M 41.9 M 38.9 M - 36.1 M 34.7 M 34.8 M - 35.6 M 36.8 M 34.9 M - 32.2 M 31.7 M 31.7 M - 32.2 M 31.2 M 29.6 M - 24.8 M 24.3 M 23 M - 20.1 M 23 M 22.8 M - 19.2 M 21 M 18.7 M - 18.7 M 17.3 M 17.3 M - 16 M 14.9 M 12.9 M 12.1 M 12.1 M 11.5 M 9.6 M 9.01 M 8.17 M 8.45 M 7.84 M 7.55 M 7.24 M 8.25 M 7.39 M

General and Administrative Expenses

22.9 M 19.9 M 18.6 M 21.2 M 20.3 M 17.8 M 19 M 19.8 M 16.2 M 20.5 M 21.6 M - 19.9 M 19.5 M 20.7 M - 20.4 M 19.8 M 19.2 M - 16.3 M 16.1 M 15.9 M - 16.1 M 16.7 M 16.2 M - 14 M 14.4 M 13.6 M - 12.2 M 14.1 M 13.7 M - 12.2 M 12.4 M 11.7 M - 10.9 M 12.1 M 11.7 M - 8.72 M 10.1 M 8.24 M 7.43 M 7.73 M 7.95 M 6.85 M 6.79 M 6.22 M 6.69 M 5.97 M 5.94 M 5.38 M 6.21 M 5.53 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Cerus Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Codexis Codexis
CDXS
$ 1.42 0.33 % $ 124 M usaUSA
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Cue Biopharma Cue Biopharma
CUE
$ 27.67 2.63 % $ 2.62 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Editas Medicine Editas Medicine
EDIT
$ 3.08 0.33 % $ 273 M usaUSA
Ardelyx Ardelyx
ARDX
$ 3.71 1.06 % $ 894 M usaUSA
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
EyePoint Pharmaceuticals EyePoint Pharmaceuticals
EYPT
$ 4.57 0.21 % $ 335 K usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.66 0.04 % $ 3.01 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 36.13 4.38 % $ 405 M usaUSA
Fate Therapeutics Fate Therapeutics
FATE
$ 2.42 0.61 % $ 287 M usaUSA
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 6.66 5.38 % $ 4.45 M usaUSA
Fortress Biotech Fortress Biotech
FBIO
$ 2.71 0.04 % $ 75.6 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.0 2.08 % $ 301 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 208.35 0.16 % $ 10.4 B usaUSA
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 57.46 2.9 % $ 1.65 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 66.43 0.04 % $ 12.7 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands